Bio View (XTAE:BIOV) ROCE %: -50.26% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:BIOV Bio View Ltd XTAE:BIOV
41 GF Score
Price ₪0.82
GF Value ₪1.71
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Bio View ROCE %?

Bio View XTAE:BIOV +0.12% 41 ROCE % is -50.26% as of Dec. 2025. GuruFocus rates XTAE:BIOV with a GF Score™ of 41/100 and a GF Value™ of ₪1.71 (Possible Value Trap). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bio View's annualized ROCE % for the quarter that ended in Dec. 2025 was -50.26%.

Bio View  (XTAE:BIOV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bio View ROCE % Related Terms

Bio View ROCE % Historical Data

* Premium members only.

The historical data trend for Bio View's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio View ROCE % Chart

Bio View Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.10 3.49 3.57 -9.81 -51.44

Bio View Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.39 16.97 -38.19 -44.23 -50.26
XTAE:BIOV
41GF Score
Bio View Ltd XTAE:BIOV
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio View ROCE % Calculation

Bio View's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-9.028/( ( (33.623 - 9.808) + (19.885 - 8.6) )/ 2 )
=-9.028/( (23.815+11.285)/ 2 )
=-9.028/17.55
=-51.44 %

Bio View's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-8.13/( ( (28.187 - 7.121) + (19.885 - 8.6) )/ 2 )
=-8.13/( ( 21.066 + 11.285 )/ 2 )
=-8.13/16.1755
=-50.26 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -50.26% mean?
Bio View (XTAE:BIOV) has a ROCE % of -50.26% as of Dec. 2025.
Is Bio View's ROCE % too high?
Bio View's current ROCE % is -50.26%. Overall, Bio View has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bio View's ROCE % compare to ABT and SYK?
Bio View's ROCE % of -50.26% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 3.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 3.07, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 3.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio View's current ROCE % is -50.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio View stock overvalued right now?
Based on GuruFocus' analysis, Bio View (XTAE:BIOV) is currently considered Possible Value Trap. The stock's GF Value™ is ₪1.71, compared to a current price of ₪0.82 — trading 52.3% below its estimated fair value. The current ROCE % is -50.26%. Bio View's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Bio View (XTAE:BIOV), the current ROCE % is -50.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio View (XTAE:BIOV) Overvalued in 2026?

Based on GuruFocus' analysis, Bio View stock appears to be undervalued. The current stock price of ₪0.82 is trading 52.3% below its estimated GF Value™ of ₪1.71. GuruFocus considers Bio View to be Possible Value Trap.

Key valuation signals for XTAE:BIOV:

  • ROCE %: -50.26%
  • GF Value™: ₪1.71 vs. price of ₪0.82 (52.3% below fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the XTAE:BIOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio View Business Description

Address 3 Pekeris Street, Rehovot, ISR, 7670203
Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.
41GF Score

Get the complete analysis for XTAE:BIOV

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪0.82
Price
₪1.71
GF Value